Abstract
Among patient (pts) who have advanced NSCLC with EGFR driver mutations (EGFRm), most benefit from EGFR tyrosine kinase inhibitors (TKIs). The ADAURA trial showed significant improvement in disease-free survival (DFS) with the addition of the EGFR TKI, osimertinib, in resected early stage (IB-IIIA) EGFRm NSCLC pts. The objective of the POTENT study was to estimate EGFRm prevalence and assess outcomes in resected early stage EGFRm NSCLC in real-world setting in Canada.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
